Key Details
Price
$9.79Annual ROE
-42.10%Beta
2.14Events Calendar
Next earnings date:
Feb 21, 2025Recent quarterly earnings:
Nov 7, 2024Recent annual earnings:
Feb 22, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
NEW YORK, NY / ACCESS Newswire / February 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. ("Intellia Therapeutics, Inc.") (NASDAQ:NTLA) concerning possible violations of federal securities laws. Intellia issued a press release on January 9, 2025, "announc[ing] its strategic priorities and key anticipated 2025 milestones".
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. ("Intellia Therapeutics, Inc.") (NASDAQ:NTLA) concerning possible violations of federal securities laws. Intellia issued a press release on January 9, 2025, "announc[ing] its strategic priorities and key anticipated 2025 milestones".
NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. ("Intellia Therapeutics, Inc.") (NASDAQ:NTLA) concerning possible violations of federal securities laws. Intellia issued a press release on January 9, 2025, "announc[ing] its strategic priorities and key anticipated 2025 milestones".
NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. ("Intellia Therapeutics, Inc.") (NASDAQ:NTLA) concerning possible violations of federal securities laws. Intellia issued a press release on January 9, 2025, "announc[ing] its strategic priorities and key anticipated 2025 milestones".
NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ:NTLA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESS Newswire / January 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. ("Intellia Therapeutics, Inc.") (NASDAQ:NTLA) concerning possible violations of federal securities laws. Intellia issued a press release on January 9, 2025, "announc[ing] its strategic priorities and key anticipated 2025 milestones".
NEW YORK, NY / ACCESS Newswire / January 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. ("Intellia Therapeutics, Inc.") (NASDAQ:NTLA) concerning possible violations of federal securities laws. Intellia issued a press release on January 9, 2025, "announc[ing] its strategic priorities and key anticipated 2025 milestones".
NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. ("Intellia Therapeutics, Inc.") (NASDAQ:NTLA) concerning possible violations of federal securities laws. Intellia issued a press release on January 9, 2025, "announc[ing] its strategic priorities and key anticipated 2025 milestones".
NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intellia Therapeutics, Inc. ("Intellia" or "the Company") (NASDAQ:NTLA). Investors who purchased Intellia securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NTLA.
NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. ("Intellia Therapeutics, Inc.") (NASDAQ:NTLA) concerning possible violations of federal securities laws. Intellia issued a press release on January 9, 2025, "announc[ing] its strategic priorities and key anticipated 2025 milestones".
FAQ
- What is the ticker symbol for Intellia Therapeutics?
- Does Intellia Therapeutics pay dividends?
- What sector is Intellia Therapeutics in?
- What industry is Intellia Therapeutics in?
- What country is Intellia Therapeutics based in?
- When did Intellia Therapeutics go public?
- Is Intellia Therapeutics in the S&P 500?
- Is Intellia Therapeutics in the NASDAQ 100?
- Is Intellia Therapeutics in the Dow Jones?
- When was Intellia Therapeutics's last earnings report?
- When does Intellia Therapeutics report earnings?
- Should I buy Intellia Therapeutics stock now?